Incyte (INCY) Akcija Cena
Incyte Cena
Pēdējos 19 gados Incyte ieņēmumi auga par 31,7 % gadā un sasniedza 5,14 B USD. Peļņa uz akciju auga par 68,6 % gadā pēdējos 10 gados. Incyte neto marža 25,0 % ir samazinājusies salīdzinājumā ar 31,8 % pirms dažiem gadiem. Incyte 12 mēnešu konsensa mērķa cena ir 130,00 USD, ap virs kursu par 13,8 %. No 35 analītiķiem 18 iesaka pirkt — kopējais konsenss ir Pirkt.
Incyte akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Incyte biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Incyte akciju
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analītiķi pašlaik nosaka vidējo Incyte akcijas mērķa cenu 128,38 USD (mediāna: 130,00 USD), kas ir +12,4 % pret pēdējo cenu. Konsenss balstās uz 35 analītiķu vērtējumiem.
35 analītiķi pašlaik vērtē Incyte akciju: 18 iesaka pirkt, 17 turēt un 0 pārdot. 2026. gadam analītiķi sagaida, ka Incyte gūs 5,94 B USD ieņēmumus un 3,27 USD peļņu uz akciju.
Pēc pašreizējā kursa Incyte akcija maksā 101,61 EUR (114,21 USD).
Incyte akcija (INCY) tiek kotēta 8 biržās, tostarp: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
gaidāmā apgrozījums Incyte ir 5,94 B USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa Incyte ir 669,64 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
Incyte cenas un peļņas rādītājs (P/E) pašlaik ir 34,93. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Incyte akcijas vērtību.
Incyte cenas un apgrozījuma rādītājs (P/S) pašlaik ir 3,94. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Incyte akcijas vērtības mērs.
Incyte Eulerpool kvalitātes rādītājs ir 6/10.
Incyte ISIN ir US45337C1027. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Incyte WKN ir 896133. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
Incyte tikeris ir INCY. Tikeris tiek izmantots Incyte akciju tirdzniecībai biržā.
Incyte akcija
Incyte Salīdzināmo uzņēmumu grupa
Incyte Biržas kods
Incyte FIGI
Visi Incyte fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Incyte ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Incyte. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: